disulfiram has been researched along with Benign Neoplasms in 76 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the current study, by utilizing a small molecule covalent compounds library screening, we found that disulfiram (DSF), an FDA-approved chronic alcoholism drug, is a potent DJ-1 inhibitor." | 8.12 | Identifying chronic alcoholism drug disulfiram as a potent DJ-1 inhibitor for cancer therapeutics. ( Cao, J; He, P; He, Q; Jiang, L; Wen, Y; Wu, Q; Yang, B; Yuan, M; Zhang, M, 2022) |
| " In the current study, by utilizing a small molecule covalent compounds library screening, we found that disulfiram (DSF), an FDA-approved chronic alcoholism drug, is a potent DJ-1 inhibitor." | 4.12 | Identifying chronic alcoholism drug disulfiram as a potent DJ-1 inhibitor for cancer therapeutics. ( Cao, J; He, P; He, Q; Jiang, L; Wen, Y; Wu, Q; Yang, B; Yuan, M; Zhang, M, 2022) |
| "Experimental studies have indicated that disulfiram (Antabuse) has antineoplastic effects against melanoma, breast, and prostate cancer." | 3.80 | Use of disulfiram and risk of cancer: a population-based case-control study. ( Askgaard, G; Friis, S; Hallas, J; Pottegård, A; Thygesen, LC, 2014) |
| "Disulfiram and metals inactivate key oncoproteins resulting in anti-neoplastic activity." | 3.01 | A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker. ( Agarwal, N; Akerley, WL; Boucher, KM; Brittain-Blankenship, M; Buys, SS; Grossman, KF; Kelley, KC; Kennedy, TP; Kosak, KM; McGregor, KA; Sborov, DW; Shami, PJ; Sharma, S; Terrazas, MC; Thorne, KM; Ward, JH; Weis, JR; Werner, TL, 2021) |
| "DSF plays an important role in cancer treatment." | 2.82 | Disulfiram: A Food and Drug Administration-approved multifunctional role in synergistically drug delivery systems for tumor treatment. ( Guo, Y; Li, Y; Shen, JW; Shen, Q; Sun, J; Sun, Y; Wei, Q; Xu, L, 2022) |
| "Disulfiram (DSF), which was originally approved as an anti-alcoholism drug, has been proven safe and shows the potential to target tumours." | 2.72 | Disulfiram: a novel repurposed drug for cancer therapy. ( Li, X; Lu, C; Ren, Y; Zhang, X, 2021) |
| "Disulfiram (DSF) is a thiuram derivative that was developed to treat alcoholism but was also found to have antitumor activity." | 2.66 | The combination of disulfiram and copper for cancer treatment. ( Chen, ZS; Cui, W; Li, H; Wang, J; Wang, L; Wu, C, 2020) |
| "Despite its excellent anticancer efficacy, the pharmaceutical significance and clinical applicability of DSF are hampered due to poor stability, low solubility, short plasma half-life, rapid metabolism, and early clearance from systemic circulation." | 2.61 | Recent advances in the delivery of disulfiram: a critical analysis of promising approaches to improve its pharmacokinetic profile and anticancer efficacy. ( Ahmad, MM; Ahsan, A; Ahsan, HM; Aquib, M; Baig, MMFA; Farooq, MA; Hussain, Z; Jiajie, J; Khan, DH; Wande, DP; Wang, B, 2019) |
| "Despite years of success of most anti-cancer drugs, one of the major clinical problems is inherent and acquired resistance to these drugs." | 2.61 | Repurposing Disulfiram as An Anti-Cancer Agent: Updated Review on Literature and Patents. ( Dou, QP; Ekinci, E; Khan, R; Rohondia, S, 2019) |
| "Accumulation of formaldehyde in cancer cells is combined with activation of the processes of cellular formaldehyde clearance." | 2.58 | Human Endogenous Formaldehyde as an Anticancer Metabolite: Its Oxidation Downregulation May Be a Means of Improving Therapy. ( Bialik, TE; Dorokhov, YL; Komarova, TV; Sheshukova, EV, 2018) |
| "There are two major hurdles in anticancer drug development: dose-limiting toxic side effects that reduce either drug effectiveness or the quality of life of patients and complicated drug development processes that are costly and time consuming." | 2.53 | Revisiting Non-Cancer Drugs for Cancer Therapy. ( Liu, Y; Lv, J; Sup Shim, J; Wu, C; Yang, EJ, 2016) |
| "DSF's anticancer activity has been demonstrated in both in vitro and in vivo model systems, and has been tested in human clinical trials for various cancer types." | 2.53 | Disulfiram's Anticancer Activity: Evidence and Mechanisms. ( Ding, WQ; Hannafon, BN; Jiao, Y, 2016) |
| "Disulfiram is a FDA approved drug for the treatment of alcoholism and available for clinical use since over 5 decades." | 2.47 | Disulfiram, and disulfiram derivatives as novel potential anticancer drugs targeting the ubiquitin-proteasome system in both preclinical and clinical studies. ( Buac, D; Kona, FR; M Burger, A, 2011) |
| "Disulfiram is a readily available and inexpensive substance whose adverse effects are negligible, compared to classical cancerostatics." | 2.44 | The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor? ( Cvek, B; Dvorak, Z, 2008) |
| "Disulfiram has long been used in the treatment of alcohol dependency and multiple clinical trials to evaluate its clinical value in oncology are ongoing." | 1.91 | Actionable cancer vulnerability due to translational arrest, p53 aggregation and ribosome biogenesis stress evoked by the disulfiram metabolite CuET. ( Andújar-Sánchez, M; Arampatzis, S; Bartek, J; Bartkova, J; Björkman, A; Espinoza, JA; Fernandez-Capetillo, O; Kanellis, DC; Kosar, M; Lemmens, B; Li, X; Lindström, MS; Mistrik, M; Skrott, Z; Zisi, A, 2023) |
| "Disulfiram (DSF) is an FDA-approved medicine for the treatment of alcoholism; however, it was later revealed to have anticancer properties." | 1.72 | Repurposing Disulfiram as a Chemo-Therapeutic Sensitizer: Molecular Targets and Mechanisms. ( Hong, B; Nie, J; Sun, F; Wang, H, 2022) |
| "Conventional treatments for cancer, such as chemotherapy, surgical resection, and radiotherapy, have shown limited therapeutic efficacy, with severe side effects, lack of targeting and drug resistance for monotherapies, which limit their clinical application." | 1.72 | A multifunctional theranostics nanosystem featuring self-assembly of alcohol-abuse drug and photosensitizers for synergistic cancer therapy. ( Jiang, JL; Li, C; Lin, JF; Shao, JW; Shen, ZC; Wu, PY; Zhang, BC; Zhang, WZ; Zou, JJ, 2022) |
| "ALDH is also a cellular marker of cancer stem cells (CSCs), which plays an important role in cancer diagnosis and prognosis assessment." | 1.72 | Near-Infrared Fluorescence Probe with a New Recognition Moiety for Specific Detection and Imaging of Aldehyde Dehydrogenase Expecting the Identification and Isolation of Cancer Stem Cells. ( Hao, Y; Li, Z; Wang, Q; Zhang, C; Zhang, Y, 2022) |
| "Here, we compare in parallel, the anti-cancer efficacy of low doses of TTM and DSF, asking whether they can be synergistic or antagonistic." | 1.56 | Cancer Pro-oxidant Therapy Through Copper Redox Cycling: ( Rieber, M, 2020) |
| "Anti-cancer uses of non-oncology drugs have occasionally been found, but such discoveries have been serendipitous." | 1.56 | Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling. ( Ben-David, U; Bender, SA; Bittker, JA; Boehm, JS; Bryan, JG; Chen, Y; Corsello, SM; Doench, JG; Dumont, N; Garvie, CW; Golub, TR; Greulich, H; Harrington, CN; Humeidi, R; Kocak, M; Lemire, E; Lyons, NJ; Mader, CC; McFarland, JM; Meyerson, M; Montgomery, P; Nagari, RT; Narayan, R; O'Hearn, PJ; Peck, D; Rees, MG; Rossen, J; Roth, JA; Spangler, RD; Stefan, E; Subramanian, A; Tang, AA; Tsherniak, A; Vazquez, F; Wang, L; Wang, VM; Wong, BT; Wu, X, 2020) |
| "Studies of breast cancer therapy have examined the improvement of bispecific trastuzumab/pertuzumab antibodies interacting simultaneously with two different epitopes of the human epidermal growth factor receptor 2 (HER2)." | 1.51 | The biological activity of bispecific trastuzumab/pertuzumab plant biosimilars may be drastically boosted by disulfiram increasing formaldehyde accumulation in cancer cells. ( Byalik, TE; Dorokhov, YL; Komarova, TV; Kosobokova, EN; Kosorukov, VS; Lipskerov, FA; Sheshukova, EV; Shindyapina, AV; Shpudeiko, PS, 2019) |
| "Disulfiram reduced cancer mortality in patients who continued disulfiram for alcohol dependency." | 1.48 | The Alcohol-Abuse Drug Disulfiram Targets NPL4 to Exert Antitumor Effects. ( , 2018) |
| "The strong anticancer activity of disulfiram is hindered by its rapid degradation in blood system." | 1.43 | The inhibitory effect of disulfiram encapsulated PLGA NPs on tumor growth: Different administration routes. ( Faghihi, S; Fasehee, H; Ghaffari, SH; Tavangar, SM; Zarrinrad, G, 2016) |
| "This manuever does not diminish the anticancer activity of cisplatin in these rats." | 1.27 | Cisplatin chronotherapy and disulfiram rescue reduce toxicity without interfering with anticancer activity: animal findings and preliminary clinical experiences. ( Berestka, J; Hrushesky, WJ; Lakatua, D; Langevin, T; Olshefski, R; Reusch, JE; Reusch, JJ; Roemeling, RV; Wick, MR, 1986) |
| "No tumors were detected in groups receiving either normal diet or normal diet supplemented with BHA, disulfiram, calcium chloride or PVP." | 1.26 | Inhibition of carcinogenic effect of bracken fern (Pteridium aquilinum) by various chemicals. ( Bryan, GT; Pamukcu, AM; Yalçiner, S, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (17.11) | 18.7374 |
| 1990's | 2 (2.63) | 18.2507 |
| 2000's | 5 (6.58) | 29.6817 |
| 2010's | 26 (34.21) | 24.3611 |
| 2020's | 30 (39.47) | 2.80 |
| Authors | Studies |
|---|---|
| Diamandis, P | 1 |
| Wildenhain, J | 1 |
| Clarke, ID | 1 |
| Sacher, AG | 1 |
| Graham, J | 1 |
| Bellows, DS | 1 |
| Ling, EK | 1 |
| Ward, RJ | 1 |
| Jamieson, LG | 1 |
| Tyers, M | 1 |
| Dirks, PB | 1 |
| Lin, R | 1 |
| Elf, S | 1 |
| Shan, C | 1 |
| Kang, HB | 1 |
| Ji, Q | 1 |
| Zhou, L | 1 |
| Hitosugi, T | 1 |
| Zhang, L | 2 |
| Zhang, S | 1 |
| Seo, JH | 1 |
| Xie, J | 1 |
| Tucker, M | 1 |
| Gu, TL | 1 |
| Sudderth, J | 1 |
| Jiang, L | 2 |
| Mitsche, M | 1 |
| DeBerardinis, RJ | 1 |
| Wu, S | 1 |
| Li, Y | 5 |
| Mao, H | 1 |
| Chen, PR | 1 |
| Wang, D | 1 |
| Chen, GZ | 1 |
| Hurwitz, SJ | 1 |
| Lonial, S | 1 |
| Arellano, ML | 1 |
| Khoury, HJ | 1 |
| Khuri, FR | 1 |
| Lee, BH | 1 |
| Lei, Q | 1 |
| Brat, DJ | 1 |
| Ye, K | 1 |
| Boggon, TJ | 1 |
| He, C | 1 |
| Kang, S | 1 |
| Fan, J | 1 |
| Chen, J | 1 |
| Shen, J | 1 |
| Zhou, W | 2 |
| Jia, M | 1 |
| Yang, X | 1 |
| Lin, J | 2 |
| An, L | 1 |
| Tian, Q | 1 |
| Yang, S | 1 |
| Krastev, DB | 1 |
| Li, S | 2 |
| Sun, Y | 2 |
| Wicks, AJ | 1 |
| Hoslett, G | 1 |
| Weekes, D | 1 |
| Badder, LM | 1 |
| Knight, EG | 1 |
| Marlow, R | 1 |
| Pardo, MC | 1 |
| Yu, L | 2 |
| Talele, TT | 1 |
| Bartek, J | 4 |
| Choudhary, JS | 1 |
| Pommier, Y | 1 |
| Pettitt, SJ | 1 |
| Tutt, ANJ | 1 |
| Ramadan, K | 1 |
| Lord, CJ | 1 |
| Sun, F | 1 |
| Wang, H | 1 |
| Nie, J | 1 |
| Hong, B | 1 |
| Wu, Q | 1 |
| Zhang, M | 1 |
| Wen, Y | 1 |
| He, P | 1 |
| He, Q | 1 |
| Yang, B | 1 |
| Yuan, M | 1 |
| Cao, J | 1 |
| Wang, L | 3 |
| Yu, Y | 1 |
| Zhou, C | 1 |
| Wan, R | 1 |
| Zhao, L | 1 |
| Wang, X | 1 |
| Lou, H | 1 |
| Jiang, M | 1 |
| Wu, X | 2 |
| Qin, J | 1 |
| Zhang, J | 1 |
| Guan, X | 1 |
| Li, W | 2 |
| Zhang, W | 1 |
| Ma, J | 1 |
| Dosset, M | 1 |
| Zanetti, M | 1 |
| Xu, L | 1 |
| Sun, J | 1 |
| Guo, Y | 1 |
| Shen, Q | 1 |
| Wei, Q | 1 |
| Shen, JW | 1 |
| Wu, PY | 1 |
| Shen, ZC | 1 |
| Jiang, JL | 1 |
| Zhang, BC | 1 |
| Zhang, WZ | 1 |
| Zou, JJ | 1 |
| Lin, JF | 1 |
| Li, C | 1 |
| Shao, JW | 1 |
| Li, Q | 1 |
| Chao, Y | 1 |
| Liu, B | 1 |
| Xiao, Z | 1 |
| Yang, Z | 1 |
| Wu, Y | 1 |
| Liu, Z | 1 |
| Wang, Q | 3 |
| Li, Z | 3 |
| Hao, Y | 3 |
| Zhang, Y | 6 |
| Zhang, C | 3 |
| Li, T | 2 |
| Zhu, J | 2 |
| Zhang, F | 1 |
| Xu, A | 1 |
| Zhou, T | 1 |
| Liu, M | 2 |
| Ke, H | 1 |
| Yang, T | 1 |
| Tang, Y | 1 |
| Tao, J | 1 |
| Miao, L | 1 |
| Deng, Y | 1 |
| Chen, H | 1 |
| Zhou, J | 1 |
| Yu, Q | 1 |
| Song, J | 1 |
| Li, XL | 1 |
| Kang, BK | 1 |
| Chen, HY | 1 |
| Xu, JJ | 1 |
| Zuo, J | 1 |
| Hao, S | 1 |
| Huang, H | 1 |
| Guo, H | 1 |
| Ni, C | 2 |
| Ouyang, Z | 1 |
| Li, G | 1 |
| Liu, J | 2 |
| Cao, X | 1 |
| Zheng, L | 1 |
| Shi, X | 1 |
| Guo, R | 2 |
| Kanellis, DC | 1 |
| Zisi, A | 1 |
| Skrott, Z | 4 |
| Lemmens, B | 1 |
| Espinoza, JA | 1 |
| Kosar, M | 1 |
| Björkman, A | 1 |
| Li, X | 3 |
| Arampatzis, S | 1 |
| Bartkova, J | 2 |
| Andújar-Sánchez, M | 1 |
| Fernandez-Capetillo, O | 1 |
| Mistrik, M | 4 |
| Lindström, MS | 1 |
| Scrima, S | 1 |
| Tiberti, M | 1 |
| Ryde, U | 1 |
| Lambrughi, M | 1 |
| Papaleo, E | 1 |
| Loffelmann, M | 1 |
| Majera, D | 3 |
| Štarha, P | 1 |
| Kryštof, V | 1 |
| Yang, Q | 1 |
| Yao, Y | 1 |
| Li, K | 1 |
| Jiao, L | 1 |
| Li, M | 1 |
| Dou, QP | 4 |
| Yang, H | 1 |
| Hwang, S | 1 |
| Shin, DM | 1 |
| Hong, JH | 1 |
| Pan, Q | 1 |
| Zhang, B | 1 |
| Peng, X | 1 |
| Wan, S | 1 |
| Luo, K | 1 |
| Gao, W | 1 |
| Pu, Y | 2 |
| He, B | 1 |
| Komarova, TV | 2 |
| Sheshukova, EV | 2 |
| Kosobokova, EN | 1 |
| Kosorukov, VS | 1 |
| Shindyapina, AV | 1 |
| Lipskerov, FA | 1 |
| Shpudeiko, PS | 1 |
| Byalik, TE | 1 |
| Dorokhov, YL | 2 |
| Farooq, MA | 1 |
| Aquib, M | 1 |
| Khan, DH | 1 |
| Hussain, Z | 1 |
| Ahsan, A | 1 |
| Baig, MMFA | 1 |
| Wande, DP | 1 |
| Ahmad, MM | 1 |
| Ahsan, HM | 1 |
| Jiajie, J | 1 |
| Wang, B | 2 |
| Chroma, K | 1 |
| Merchut-Maya, JM | 1 |
| Wu, W | 1 |
| Yao, H | 1 |
| Chen, Y | 2 |
| Shi, J | 1 |
| Li, H | 1 |
| Wang, J | 1 |
| Wu, C | 3 |
| Chen, ZS | 1 |
| Cui, W | 1 |
| Sertedaki, E | 1 |
| Kotsinas, A | 1 |
| Peng, Y | 1 |
| Liu, P | 1 |
| Meng, Y | 1 |
| Hu, S | 1 |
| Ding, J | 1 |
| Rieber, M | 1 |
| Corsello, SM | 1 |
| Nagari, RT | 1 |
| Spangler, RD | 1 |
| Rossen, J | 1 |
| Kocak, M | 1 |
| Bryan, JG | 1 |
| Humeidi, R | 1 |
| Peck, D | 1 |
| Tang, AA | 1 |
| Wang, VM | 1 |
| Bender, SA | 1 |
| Lemire, E | 1 |
| Narayan, R | 1 |
| Montgomery, P | 1 |
| Ben-David, U | 1 |
| Garvie, CW | 1 |
| Rees, MG | 1 |
| Lyons, NJ | 1 |
| McFarland, JM | 1 |
| Wong, BT | 1 |
| Dumont, N | 1 |
| O'Hearn, PJ | 1 |
| Stefan, E | 1 |
| Doench, JG | 1 |
| Harrington, CN | 1 |
| Greulich, H | 1 |
| Meyerson, M | 1 |
| Vazquez, F | 1 |
| Subramanian, A | 1 |
| Roth, JA | 1 |
| Bittker, JA | 1 |
| Boehm, JS | 1 |
| Mader, CC | 1 |
| Tsherniak, A | 1 |
| Golub, TR | 1 |
| Shi, H | 1 |
| Suo, Y | 1 |
| Zhang, Z | 1 |
| Liu, R | 1 |
| Liu, H | 1 |
| Cheng, Z | 1 |
| Lu, C | 1 |
| Ren, Y | 1 |
| Zhang, X | 1 |
| Najlah, M | 1 |
| Tang, C | 1 |
| Pang, X | 1 |
| Guo, Z | 1 |
| Liu, L | 1 |
| Chen, X | 1 |
| Kelley, KC | 1 |
| Grossman, KF | 1 |
| Brittain-Blankenship, M | 1 |
| Thorne, KM | 1 |
| Akerley, WL | 1 |
| Terrazas, MC | 1 |
| Kosak, KM | 1 |
| Boucher, KM | 1 |
| Buys, SS | 1 |
| McGregor, KA | 1 |
| Werner, TL | 1 |
| Agarwal, N | 1 |
| Weis, JR | 1 |
| Sharma, S | 1 |
| Ward, JH | 1 |
| Kennedy, TP | 1 |
| Sborov, DW | 1 |
| Shami, PJ | 1 |
| Viola-Rhenals, M | 1 |
| Patel, KR | 1 |
| Jaimes-Santamaria, L | 1 |
| Wu, G | 1 |
| Andersen, KK | 1 |
| Friis, S | 2 |
| Gursky, J | 1 |
| Ozdian, T | 1 |
| Turi, Z | 1 |
| Moudry, P | 1 |
| Kraus, M | 1 |
| Michalova, M | 1 |
| Vaclavkova, J | 1 |
| Dzubak, P | 1 |
| Vrobel, I | 1 |
| Pouckova, P | 1 |
| Sedlacek, J | 1 |
| Miklovicova, A | 1 |
| Kutt, A | 1 |
| Li, J | 2 |
| Mattova, J | 1 |
| Driessen, C | 1 |
| Olsen, J | 1 |
| Hajduch, M | 1 |
| Cvek, B | 4 |
| Deshaies, RJ | 1 |
| He, H | 1 |
| Markoutsa, E | 1 |
| Xu, P | 1 |
| Bialik, TE | 1 |
| An, S | 1 |
| Tang, M | 1 |
| Yan, S | 1 |
| Yang, F | 1 |
| Zhu, X | 1 |
| Chen, Z | 1 |
| Liu, Q | 1 |
| Mohammad, IS | 1 |
| Teng, C | 1 |
| Chaurasiya, B | 1 |
| Yin, L | 1 |
| He, W | 1 |
| Banerjee, P | 1 |
| Geng, T | 1 |
| Mahanty, A | 1 |
| Zong, L | 1 |
| Ekinci, E | 1 |
| Rohondia, S | 1 |
| Khan, R | 1 |
| Freyer, DR | 1 |
| Brock, P | 1 |
| Knight, K | 1 |
| Reaman, G | 1 |
| Cabral, S | 1 |
| Robinson, PD | 1 |
| Sung, L | 1 |
| Askgaard, G | 1 |
| Hallas, J | 1 |
| Thygesen, LC | 1 |
| Pottegård, A | 1 |
| Tian, B | 1 |
| Lei, T | 1 |
| Meng, J | 1 |
| Yang, L | 1 |
| Chen, F | 1 |
| Zhang, H | 1 |
| Xu, H | 1 |
| Tang, X | 1 |
| Yang, EJ | 1 |
| Liu, Y | 1 |
| Lv, J | 1 |
| Sup Shim, J | 1 |
| Fasehee, H | 1 |
| Zarrinrad, G | 1 |
| Tavangar, SM | 1 |
| Ghaffari, SH | 1 |
| Faghihi, S | 1 |
| Jiao, Y | 1 |
| Hannafon, BN | 1 |
| Ding, WQ | 1 |
| Dvorak, Z | 1 |
| Kona, FR | 1 |
| Buac, D | 1 |
| M Burger, A | 1 |
| Zhu, W | 1 |
| Lee, CY | 1 |
| Johnson, RL | 1 |
| Wichterman, J | 1 |
| Huang, R | 1 |
| DePamphilis, ML | 1 |
| Lin, LZ | 1 |
| Sauna, ZE | 1 |
| Shukla, S | 1 |
| Ambudkar, SV | 1 |
| Wilkin, JK | 1 |
| Epstein, LH | 1 |
| Ershler, WB | 1 |
| Hacker, MP | 1 |
| Newman, RA | 1 |
| Stewart, JA | 1 |
| Gamelli, RL | 1 |
| Krakoff, IH | 1 |
| Griffin, AC | 1 |
| Vastag, B | 1 |
| Loo, TW | 1 |
| Clarke, DM | 1 |
| Wattenberg, LW | 2 |
| Plotnick, HB | 1 |
| Yodaiken, RE | 1 |
| Pamukcu, AM | 1 |
| Yalçiner, S | 1 |
| Bryan, GT | 1 |
| Van Duuren, BL | 1 |
| Verma, S | 2 |
| Stewart, DJ | 2 |
| Maroun, JA | 2 |
| Nair, RC | 1 |
| Pötzsch, J | 1 |
| Schramm, T | 2 |
| Roemeling, RV | 1 |
| Olshefski, R | 1 |
| Langevin, T | 1 |
| Berestka, J | 1 |
| Reusch, JJ | 1 |
| Reusch, JE | 1 |
| Lakatua, D | 1 |
| Wick, MR | 1 |
| Hrushesky, WJ | 1 |
| Bender, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Study of Disulfiram and Copper Gluconate for the Treatment of Refractory Solid Tumors Involving the Liver[NCT00742911] | Phase 1 | 21 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| A Phase 3 Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy Incorporating a Randomized Assessment of Sodium Thiosulfate as Otoprotection for Children With Localized Disease, and Respons[NCT04478292] | Phase 3 | 330 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | ||
| Phase II Open Labeled Trial of Disulfiram With Copper in Metastatic Breast Cancer[NCT03323346] | Phase 2 | 150 participants (Anticipated) | Interventional | 2017-09-29 | Recruiting | ||
| DIRECT (DIsulfiram REsponse as add-on to ChemoTherapy in Recurrent) Glioblastoma: A Randomized Controlled Trial[NCT02678975] | Phase 2/Phase 3 | 88 participants (Actual) | Interventional | 2017-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
23 reviews available for disulfiram and Benign Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
Anticancer effects of disulfiram: a systematic review of in vitro, animal, and human studies.
Topics: Animals; Antineoplastic Agents; Disulfiram; Humans; Neoplasms | 2022 |
Disulfiram: A Food and Drug Administration-approved multifunctional role in synergistically drug delivery systems for tumor treatment.
Topics: Antineoplastic Agents; Cell Line, Tumor; Copper; Disulfiram; Ditiocarb; Drug Delivery Systems; Human | 2022 |
An Updated Review of Disulfiram: Molecular Targets and Strategies for Cancer Treatment.
Topics: Disulfiram; Humans; Neoplasm Metastasis; Neoplasms; Neoplastic Stem Cells; Proteasome Endopeptidase | 2019 |
Recent advances in the delivery of disulfiram: a critical analysis of promising approaches to improve its pharmacokinetic profile and anticancer efficacy.
Topics: Animals; Antineoplastic Agents; Disulfiram; Drug Carriers; Half-Life; Humans; Nanoparticles; Neoplas | 2019 |
The combination of disulfiram and copper for cancer treatment.
Topics: Animals; Antineoplastic Agents; Copper; Disulfiram; Drug Therapy, Combination; Humans; Neoplasms | 2020 |
Disulfiram: a novel repurposed drug for cancer therapy.
Topics: Animals; Antineoplastic Agents; Disulfiram; Drug Repositioning; Humans; Neoplasms; Neoplastic Stem C | 2021 |
Recent Advances in Antabuse (Disulfiram): The Importance of its Metal-binding Ability to its Anticancer Activity.
Topics: Acetaldehyde Dehydrogenase Inhibitors; Antineoplastic Agents; Disulfiram; Drug Repositioning; Humans | 2018 |
Human Endogenous Formaldehyde as an Anticancer Metabolite: Its Oxidation Downregulation May Be a Means of Improving Therapy.
Topics: Acetaldehyde Dehydrogenase Inhibitors; Aldehyde Dehydrogenase; Antineoplastic Agents; Biomarkers, Tu | 2018 |
Repurposing Disulfiram as An Anti-Cancer Agent: Updated Review on Literature and Patents.
Topics: Animals; Antineoplastic Agents; Disulfiram; Drug Repositioning; Humans; Neoplasms; Patents as Topic; | 2019 |
Interventions for cisplatin-induced hearing loss in children and adolescents with cancer.
Topics: Acetylcysteine; Adolescent; Amifostine; Anti-Inflammatory Agents; Antineoplastic Agents; Chelating A | 2019 |
Revisiting Non-Cancer Drugs for Cancer Therapy.
Topics: Antineoplastic Agents; Disulfiram; Doxycycline; Drug Repositioning; High-Throughput Screening Assays | 2016 |
Disulfiram's Anticancer Activity: Evidence and Mechanisms.
Topics: Aldehyde Dehydrogenase; Animals; Antineoplastic Agents; Cell Proliferation; Disulfiram; Enzyme Inhib | 2016 |
The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor?
Topics: Alcohol Deterrents; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Disulfiram; Drug Scre | 2008 |
Disulfiram, and disulfiram derivatives as novel potential anticancer drugs targeting the ubiquitin-proteasome system in both preclinical and clinical studies.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Disulfiram; Drug Evaluation, Preclinical; | 2011 |
Targeting malignancies with disulfiram (Antabuse): multidrug resistance, angiogenesis, and proteasome.
Topics: Clinical Trials as Topic; Disulfiram; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; | 2011 |
Disulfiram, an old drug with new potential therapeutic uses for human cancers and fungal infections.
Topics: Antifungal Agents; Antineoplastic Agents; Disulfiram; Humans; Models, Biological; Molecular Structur | 2005 |
Flushing reactions: consequences and mechanisms.
Topics: Chlorpropamide; Disulfiram; Drug Interactions; Endorphins; Ethanol; Female; Glutamates; Hot Temperat | 1981 |
The direct effects of compliance on health outcome.
Topics: Alcoholism; Chlorpromazine; Chorionic Gonadotropin; Clofibrate; Coronary Disease; Disulfiram; Drug T | 1984 |
Cancer chemoprevention.
Topics: Animals; Antioxidants; Butylated Hydroxytoluene; Carcinogens; Disulfiram; Drug Therapy; Female; Huma | 1980 |
Inhibition of chemical carcinogenesis.
Topics: Animals; Butylated Hydroxyanisole; Butylated Hydroxytoluene; Carcinogens; Disulfiram; Enzyme Inducti | 1978 |
Inhibition of carcinogenesis by minor anutrient constituents of the diet.
Topics: Allium; Animals; Citrus; Diet; Disulfiram; Humans; Isothiocyanates; Neoplasms; Terpenes; Thiocyanate | 1990 |
[Chemoprevention of cancer--present status, problems and trends].
Topics: Animals; Antioxidants; Disulfiram; Humans; Neoplasms; Neoplasms, Experimental; Phenols; Retinoids; S | 1987 |
3 trials available for disulfiram and Benign Neoplasms
| Article | Year |
|---|---|
A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker.
Topics: Adult; Aged; Aged, 80 and over; Disulfiram; Dose-Response Relationship, Drug; Female; Gluconates; Gl | 2021 |
The direct effects of compliance on health outcome.
Topics: Alcoholism; Chlorpromazine; Chorionic Gonadotropin; Clofibrate; Coronary Disease; Disulfiram; Drug T | 1984 |
A randomized phase II study of cisplatin alone versus cisplatin plus disulfiram.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disulfiram; Female; Humans; Male; M | 1990 |
51 other studies available for disulfiram and Benign Neoplasms
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic | 2007 |
Tumor Microenvironment-Responsive Reagent DFS@HKUST-1 for Photoacoustic Imaging-Guided Multimethod Therapy.
Topics: Copper; Disulfiram; Humans; Hydrogen Peroxide; Indicators and Reagents; Metal-Organic Frameworks; Ne | 2021 |
The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin.
Topics: Cell Line, Tumor; Chromatin; Disulfiram; HCT116 Cells; HeLa Cells; Humans; MCF-7 Cells; Neoplasms; N | 2022 |
Repurposing Disulfiram as a Chemo-Therapeutic Sensitizer: Molecular Targets and Mechanisms.
Topics: Antineoplastic Agents; Cell Line, Tumor; Copper; Disulfiram; Drug Repositioning; Humans; Neoplasms | 2022 |
Identifying chronic alcoholism drug disulfiram as a potent DJ-1 inhibitor for cancer therapeutics.
Topics: Alcohol Deterrents; Alcoholism; Antineoplastic Agents; Cell Line, Tumor; Chronic Disease; Copper; Di | 2022 |
Buffet-style Cu(II) for enhance disulfiram-based cancer therapy.
Topics: Antineoplastic Agents; Cell Line, Tumor; Copper; Disulfiram; Hydrogen Peroxide; Neoplasms | 2022 |
Disulfiram's journey from rubber vulcanization to T-cell activation.
Topics: Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Neoplasms; Rubber | 2022 |
A multifunctional theranostics nanosystem featuring self-assembly of alcohol-abuse drug and photosensitizers for synergistic cancer therapy.
Topics: Cell Line, Tumor; Delayed-Action Preparations; Dendrimers; Disulfiram; Doxorubicin; Drug Delivery Sy | 2022 |
Disulfiram loaded calcium phosphate nanoparticles for enhanced cancer immunotherapy.
Topics: Antineoplastic Agents; Calcium Phosphates; Cell Line, Tumor; Copper; Disulfiram; Immunotherapy; Nano | 2022 |
Near-Infrared Fluorescence Probe with a New Recognition Moiety for Specific Detection and Imaging of Aldehyde Dehydrogenase Expecting the Identification and Isolation of Cancer Stem Cells.
Topics: Aldehyde Dehydrogenase; Disulfiram; Fluorescent Dyes; Humans; Neoplasms; Neoplastic Stem Cells | 2022 |
Near-Infrared Fluorescence Probe with a New Recognition Moiety for Specific Detection and Imaging of Aldehyde Dehydrogenase Expecting the Identification and Isolation of Cancer Stem Cells.
Topics: Aldehyde Dehydrogenase; Disulfiram; Fluorescent Dyes; Humans; Neoplasms; Neoplastic Stem Cells | 2022 |
Near-Infrared Fluorescence Probe with a New Recognition Moiety for Specific Detection and Imaging of Aldehyde Dehydrogenase Expecting the Identification and Isolation of Cancer Stem Cells.
Topics: Aldehyde Dehydrogenase; Disulfiram; Fluorescent Dyes; Humans; Neoplasms; Neoplastic Stem Cells | 2022 |
Near-Infrared Fluorescence Probe with a New Recognition Moiety for Specific Detection and Imaging of Aldehyde Dehydrogenase Expecting the Identification and Isolation of Cancer Stem Cells.
Topics: Aldehyde Dehydrogenase; Disulfiram; Fluorescent Dyes; Humans; Neoplasms; Neoplastic Stem Cells | 2022 |
A pH-Activatable Copper-Biomineralized Proenzyme for Synergistic Chemodynamic/Chemo-Immunotherapy against Aggressive Cancers.
Topics: Cell Line, Tumor; Copper; Disulfiram; Enzyme Precursors; Glutathione; Humans; Hydrogen Peroxide; Hyd | 2023 |
Photothermally Triggered Copper Payload Release for Cuproptosis-Promoted Cancer Synergistic Therapy.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Copper; Disulfiram; Ditiocarb; Humans; Neoplasms | 2023 |
pH-responsive nanocatalyst for enhancing cancer therapy
Topics: Disulfiram; Engineering; Glutathione; Homeostasis; Hydrogen Peroxide; Hydrogen-Ion Concentration; Ne | 2023 |
A tumor microenvironment-responsive core-shell tecto dendrimer nanoplatform for magnetic resonance imaging-guided and cuproptosis-promoted chemo-chemodynamic therapy.
Topics: Apoptosis; Cell Line, Tumor; Copper; Dendrimers; Disulfiram; Humans; Magnetic Resonance Imaging; Nan | 2023 |
Actionable cancer vulnerability due to translational arrest, p53 aggregation and ribosome biogenesis stress evoked by the disulfiram metabolite CuET.
Topics: Animals; Cell Line, Tumor; Disulfiram; Humans; Neoplasms; Ribosomes; Tumor Suppressor Protein p53; Z | 2023 |
Comparison of force fields to study the zinc-finger containing protein NPL4, a target for disulfiram in cancer therapy.
Topics: Copper; Disulfiram; Humans; Ions; Neoplasms; Proteins; Zinc | 2023 |
Identification of novel dithiocarbamate-copper complexes targeting p97/NPL4 pathway in cancer cells.
Topics: Copper; Disulfiram; Neoplasms; Proteasome Endopeptidase Complex; Proteins; Ubiquitin | 2023 |
Drug Repurposing as an Antitumor Agent: Disulfiram-Mediated Carbonic Anhydrase 12 and Anion Exchanger 2 Modulation to Inhibit Cancer Cell Migration.
Topics: Antineoplastic Agents; Carbonic Anhydrases; Cell Line, Tumor; Cell Membrane; Cell Movement; Chloride | 2019 |
A dithiocarbamate-based H
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Copper; Disulfiram; Female; Humans; | 2019 |
The biological activity of bispecific trastuzumab/pertuzumab plant biosimilars may be drastically boosted by disulfiram increasing formaldehyde accumulation in cancer cells.
Topics: Antibodies, Monoclonal, Humanized; Biosimilar Pharmaceuticals; Cell Line, Tumor; Cell Proliferation; | 2019 |
Targeting the NPL4 Adaptor of p97/VCP Segregase by Disulfiram as an Emerging Cancer Vulnerability Evokes Replication Stress and DNA Damage while Silencing the ATR Pathway.
Topics: Adaptor Proteins, Signal Transducing; Alcohol Deterrents; Ataxia Telangiectasia Mutated Proteins; Ce | 2020 |
Copper-Enriched Prussian Blue Nanomedicine for In Situ Disulfiram Toxification and Photothermal Antitumor Amplification.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Coordination Complexes; Copper; Disulfi | 2020 |
Drug Repurposing and DNA Damage in Cancer Treatment: Facts and Misconceptions.
Topics: Animals; Cell Proliferation; Disulfiram; DNA Damage; Drug Repositioning; Humans; Neoplasms | 2020 |
Nanoscale Copper(II)-Diethyldithiocarbamate Coordination Polymer as a Drug Self-Delivery System for Highly Robust and Specific Cancer Therapy.
Topics: Animals; Cell Line; Cell Line, Tumor; Copper; Disulfiram; Ditiocarb; Drug Delivery Systems; Female; | 2020 |
Cancer Pro-oxidant Therapy Through Copper Redox Cycling:
Topics: Cell Line, Tumor; Copper; Disulfiram; Drug Repositioning; Humans; Hydrogen Peroxide; Molybdenum; Neo | 2020 |
Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling.
Topics: Cell Line; Disulfiram; Drug Repositioning; Humans; Neoplasms | 2020 |
Copper(II)-disulfiram loaded melanin-dots for cancer theranostics.
Topics: Animals; Cell Line, Tumor; Copper; Disulfiram; Ditiocarb; Female; Hyperthermia, Induced; Melanins; M | 2021 |
Drug repurposing supported by nanotechnology: a promising strategy to fight cancer.
Topics: Antineoplastic Agents; Disulfiram; Drug Repositioning; Humans; Neoplasms | 2021 |
Dual Action of Acidic Microenvironment on the Enrichment of the Active Metabolite of Disulfiram in Tumor Tissues.
Topics: Acetaldehyde Dehydrogenase Inhibitors; Antineoplastic Agents; Cell Line, Tumor; Copper; Copper Trans | 2021 |
Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4.
Topics: Adult; Alcohol Deterrents; Alcoholism; Animals; Antineoplastic Agents; Copper; Denmark; Disulfiram; | 2017 |
The Alcohol-Abuse Drug Disulfiram Targets NPL4 to Exert Antitumor Effects.
Topics: Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Illicit Drugs; Neoplasms | 2018 |
Repurposing disulfiram for cancer therapy via targeted nanotechnology through enhanced tumor mass penetration and disassembly.
Topics: Acrylates; Animals; Body Weight; Cell Line, Tumor; Cell Proliferation; Disulfiram; Drug Repositionin | 2018 |
Functional duality of ethanol on cancer.
Topics: Acetic Acid; Acids; Alcohol Drinking; Alcoholism; Calcium Oxalate; Disulfiram; Ethanol; Humans; Hydr | 2019 |
Drug-delivering-drug approach-based codelivery of paclitaxel and disulfiram for treating multidrug-resistant cancer.
Topics: A549 Cells; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biologic | 2019 |
Integrating the drug, disulfiram into the vitamin E-TPGS-modified PEGylated nanostructured lipid carriers to synergize its repurposing for anti-cancer therapy of solid tumors.
Topics: Animals; Antineoplastic Agents; Blood Proteins; Cell Line, Tumor; Disulfiram; Drug Carriers; Drug Li | 2019 |
Use of disulfiram and risk of cancer: a population-based case-control study.
Topics: Aged; Alcohol Deterrents; Breast Neoplasms; Case-Control Studies; Denmark; Disulfiram; Female; Human | 2014 |
A Copper-Mediated Disulfiram-Loaded pH-Triggered PEG-Shedding TAT Peptide-Modified Lipid Nanocapsules for Use in Tumor Therapy.
Topics: Animals; Apoptosis; Cell Survival; Copper; Disulfiram; Drug Liberation; Endocytosis; Hep G2 Cells; H | 2015 |
The inhibitory effect of disulfiram encapsulated PLGA NPs on tumor growth: Different administration routes.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Disulfiram; Drug Carriers; F | 2016 |
An image-based, high-throughput screening assay for molecules that induce excess DNA replication in human cancer cells.
Topics: Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cell Proliferation; Disulfiram; DNA Replication | 2011 |
Antabuse (disulfiram) as an affordable and promising anticancer drug.
Topics: Alcohol Deterrents; Disulfiram; Drug Costs; Humans; Neoplasms | 2011 |
Nonprofit drugs as the salvation of the world's healthcare systems: the case of Antabuse (disulfiram).
Topics: Alcohol Deterrents; Delivery of Health Care; Disulfiram; Drug Industry; Humans; Neoplasms; Organizat | 2012 |
Effect of disulfiram on cyclophosphamide toxicity: a clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disulfiram; Drug Eval | 1983 |
Almost serendipity: alcoholism drug reverses drug resistance in vitro.
Topics: Alcohol Deterrents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Capsaicin; Cystic Fibro | 2000 |
Blockage of drug resistance in vitro by disulfiram, a drug used to treat alcoholism.
Topics: Adenosine Triphosphatases; Alcohol Deterrents; Aldehyde Dehydrogenase; ATP Binding Cassette Transpor | 2000 |
Carcinogenesis in rats of combined ethylene dibromide and disulfiram.
Topics: Animals; Disulfiram; Drug Interactions; Ethylene Dibromide; Female; Hydrocarbons, Brominated; Male; | 1978 |
Ethylene dibromide and disulfiram--a lethal combination.
Topics: Alcoholism; Disulfiram; Drug Synergism; Environmental Exposure; Ethylene Dibromide; Humans; Hydrocar | 1978 |
Inhibition of carcinogenic effect of bracken fern (Pteridium aquilinum) by various chemicals.
Topics: Animals; Anisoles; Butylated Hydroxyanisole; Calcium Chloride; Carcinogens, Environmental; Diet; Dis | 1977 |
On the possible mechanism of carcinogenic action of vinyl chloride.
Topics: Alkylating Agents; Animals; Disulfiram; Hemangiosarcoma; Humans; Liver Neoplasms; Mice; Neoplasms; R | 1975 |
Cisplatin chronotherapy and disulfiram rescue reduce toxicity without interfering with anticancer activity: animal findings and preliminary clinical experiences.
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Circadian Rhythm; Cisplatin; Disulfir | 1986 |
Phase I study of the combination of disulfiram with cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disulfiram; Drug Evaluation; Female; Huma | 1987 |
[Further studies of the problem of different thermosensitivity of tumor and normal cells in vitro and in vivo].
Topics: Animals; Bone Marrow; Bone Marrow Cells; Bronchial Neoplasms; Carcinoma, Ehrlich Tumor; Chickens; Cr | 1968 |